Members |
targetComponentId |
adrenalin 2,0 % opløsning |
Adrenaline only product |
epinephrin 500 µg/ml injektionsvæske, opløsning, ampul |
Adrenaline (as adrenaline acid tartrate) 500 microgram/mL solution for injection |
adrenalin 5 µg + lidocainhydrochlorid 15 mg injektionsvæske, opløsning, hætteglas |
Product containing only epinephrine and lidocaine in parenteral dose form (medicinal product form) |
adrenalin 5 µg + prilocainhydrochlorid 40 mg injektionsvæske, opløsning, hætteglas |
Adrenaline (as adrenaline acid tartrate) 5 microgram/mL and prilocaine hydrochloride 40 mg/mL solution for injection |
Epinephrine acid tartrate 0.01% conventional release eye drops |
Adrenaline only product in ocular dose form |
adrenalinbitartrat 0,01 % øjendråber uden konserveringsmiddel |
Adrenaline only product in ocular dose form |
Epinephrine acid tartrate 0.1% conventional release eye drops |
Adrenaline only product in ocular dose form |
adrenalinbitartrat 0,1 % øjendråber uden konserveringsmiddel |
Adrenaline only product in ocular dose form |
adrenalinbitartrat 1 % wt/vol + pilocarpinhydrochlorid 1 % wt/vol opløsning |
Product containing only epinephrine and pilocarpine (medicinal product) |
adrenalinbitartrat 1 % wt/vol + pilocarpinhydrochlorid 2 % wt/vol opløsning |
Product containing only epinephrine and pilocarpine (medicinal product) |
adrenalinbitartrat 1 % wt/vol + pilocarpinhydrochlorid 4 % wt/vol opløsning |
Product containing only epinephrine and pilocarpine (medicinal product) |
adrenalinbitartrat 1 % + pilocarpinhydrochlorid 6 % wt/vol opløsning |
Product containing only epinephrine and pilocarpine (medicinal product) |
adrenalinbitartrat 5 µg + lidocainhydrochlorid 10 mg injektionsvæske, opløsning, hætteglas |
Product containing only epinephrine and lidocaine in parenteral dose form (medicinal product form) |
adrenalinhydrochlorid 1 % opløsning |
Adrenaline only product |
adrenalinhydrochlorid pellet a 1,9 mg til dental anvendelse |
Adrenaline only product in dental dose form |
adrenalinhydrochlorid 2 % opløsning |
Adrenaline only product |
Epineural neurolysis |
Destruction - action |
Epiphyseal cartilage |
Structure of epiphyseal plate (body structure) |
Epiphysiolysis |
Epiphysiodesis |
Epirubicin hydrochloride 200mg/100mL solution |
Product containing precisely epirubicin hydrochloride 2 milligram/1 milliliter conventional release solution for injection (clinical drug) |
epirubicinhydrochlorid 2 mg/ml infusionsvæske, opløsning, hætteglas a 100 ml |
Product containing precisely epirubicin hydrochloride 2 milligram/1 milliliter conventional release solution for injection (clinical drug) |
Epirubicin hydrochloride 2mg/mL injection solution 100mL vial |
Product containing precisely epirubicin hydrochloride 2 milligram/1 milliliter conventional release solution for injection (clinical drug) |
episcleritis periodica fugax |
Episcleritis |
Episcleritis periodica fugax |
Episcleritis |
Episiotomy wound |
Episiotomy wound |
episodisk skadelig brug af stof |
Episodic harmful pattern of substance use |
Epitelial ovarietumor, FIGO-stadium I |
American Joint Committee on Cancer stage I (qualifier value) |
Epitelial ovarietumor, FIGO-stadium IA |
American Joint Committee on Cancer stage IA (qualifier value) |
Epitelial ovarietumor, FIGO-stadium IB |
American Joint Committee on Cancer stage IB (qualifier value) |
Epitelial ovarietumor, FIGO-stadium IC |
American Joint Committee on Cancer stage IC (qualifier value) |
Epitelial ovarietumor, FIGO-stadium IIA |
American Joint Committee on Cancer stage IIA (qualifier value) |
Epitelial ovarietumor, FIGO-stadium IIB |
American Joint Committee on Cancer stage IIB (qualifier value) |
Epitelial ovarietumor, FIGO-stadium III |
American Joint Committee on Cancer stage III (qualifier value) |
Epithelial ovarian tumor, International Federation of Gynecology and Obstetrics stage IIIA |
American Joint Committee on Cancer stage IIIA (qualifier value) |
Epithelial ovarian tumor, International Federation of Gynecology and Obstetrics stage IIIB |
American Joint Committee on Cancer stage IIIB (qualifier value) |
Epithelial ovarian tumor, International Federation of Gynecology and Obstetrics stage IIIC |
American Joint Committee on Cancer stage IIIC (qualifier value) |
Epitelial ovarietumor, FIGO-stadium IV |
American Joint Committee on Cancer stage IV (qualifier value) |
Epithelial ovarian tumour, FIGO stage IVA |
American Joint Committee on Cancer stage IVA (qualifier value) |
Epithelial ovarian tumour, FIGO stage IVB |
American Joint Committee on Cancer stage IVB (qualifier value) |
Epithelial stromal corneal dystrophy |
Epithelial basement membrane dystrophy (disorder) |
benign epitelial tumor |
Benign epithelial neoplasm |
epiteloidt hæmangioendoteliom |
Epithelioid hemangioendothelioma, malignant (morphologic abnormality) |
Epoetin alfa 10000unt/mL injection |
Product containing precisely epoetin alfa 10000 unit/1 milliliter conventional release solution for injection (clinical drug) |
epoetin alfa 10.000 enheder/ml injektionsvæske, opløsning, hætteglas a 1 ml |
Product containing precisely epoetin alfa 10000 unit/1 milliliter conventional release solution for injection (clinical drug) |
Epoetin alfa 10000unt/mL solution |
Product containing precisely epoetin alfa 10000 unit/1 milliliter conventional release solution for injection (clinical drug) |
epoetin alfa 20.000 enheder/ml injektionsvæske, opløsning, hætteglas a 1 ml |
Epoetin alfa 20000 unit/mL solution for injection |
Epoetin alfa 2000unt/mL injection |
Epoetin alfa 2000 unit/mL solution for injection |
epoetin alfa 2000 enheder/ml injektionsvæske, opløsning, hætteglas a 1 ml |
Epoetin alfa 2000 unit/mL solution for injection |
Epoetin alfa 2000unt/mL solution |
Epoetin alfa 2000 unit/mL solution for injection |
epoetin alfa 3000 enheder/ml injektionsvæske, opløsning, hætteglas a 1 ml |
Product containing precisely epoetin alfa 3000 unit/1 milliliter conventional release solution for injection (clinical drug) |
epoetin alfa 4000 enheder/ml injektionsvæske, opløsning, hætteglas a 1 ml |
Epoetin alfa 4000 unit/mL solution for injection |
Epoetin alfa 4000unt/mL solution |
Epoetin alfa 4000 unit/mL solution for injection |
epoetin beta 10.000 IE pulver og solvent til injektionsvæske, opløsning, cylinderampul |
Epoetin beta only product in parenteral dose form |
Epoetin beta 10,000iu powder for conventional release solution for injection cartridge |
Epoetin beta only product in parenteral dose form |
epoetin beta 100.000 IE pulver og solvent til injektionsvæske, opløsning, hætteglas |
Epoetin beta only product in parenteral dose form |
Epoetin beta 100,000iu powder for conventional release solution for injection vial |
Epoetin beta only product in parenteral dose form |
epoetin beta 20.000 IE pulver og solvent til injektionsvæske, opløsning, cylinderampul |
Epoetin beta only product in parenteral dose form |
Epoetin beta 20,000iu powder for conventional release solution for injection cartridge |
Epoetin beta only product in parenteral dose form |
epoetin beta 50.000 IE pulver og solvent til injektionsvæske, opløsning, hætteglas |
Epoetin beta only product in parenteral dose form |
Epoetin beta 50,000iu powder for conventional release solution for injection vial |
Epoetin beta only product in parenteral dose form |
epoetin beta 500 IE pulver og solvent til injektionsvæske, opløsning, hætteglas |
Epoetin beta only product in parenteral dose form |
epoetin beta 60.000 IE pulver og solvent til injektionsvæske, opløsning, cylinderampul |
Epoetin beta only product in parenteral dose form |
Epoetin beta 60,000iu powder for conventional release solution for injection cartridge |
Epoetin beta only product in parenteral dose form |
Epoophoron |
Wolffian body rest |
Epsteins syndrom |
MYH9-related disease (MYH9-RD) is an inherited giant platelet disorder with a complex phenotype characterized by congenital thrombocytopenia and possible subsequent manifestations of sensorineural hearing loss, presenile cataracts, elevation of liver enzymes, and/or progressive nephropathy often leading to end-stage renal disease (ESRD). Epstein syndrome, Fechtner syndrome, May-Hegglin anomaly and Sebastian syndrome, previously described as distinct disorders, represent some of the different clinical presentations of MYH9-RD. |
Eptifibatide 0.75mg injection |
Product containing precisely eptifibatide 750 microgram/1 milliliter conventional release solution for injection (clinical drug) |
Eptifibatide 0.75mg/mL injection |
Product containing precisely eptifibatide 750 microgram/1 milliliter conventional release solution for injection (clinical drug) |
Eptifibatide 0.75mg/mL injection solution 100mL bag |
Product containing precisely eptifibatide 750 microgram/1 milliliter conventional release solution for injection (clinical drug) |
eptifibatid 750 µg/ml infusionsvæske, opløsning, hætteglas a 100 ml |
Product containing precisely eptifibatide 750 microgram/1 milliliter conventional release solution for injection (clinical drug) |
anti-humant thymocytimmunglobulin fra heste 20 mg/ml injektionsvæske, opløsning, hætteglas a 5 ml |
Product containing precisely equine antithymocyte immunoglobulin 20 milligram/1 milliliter conventional release solution for injection (clinical drug) |
Equine arteritis virus antibody |
Viral antibody |
Equine infectious anemia virus antibody |
Viral antibody |
Equus asinus asinus |
Equus asinus |
røntgenundersøgelse af abdomen i opret stilling |
Erect plain X-ray of abdomen (procedure) |
Erect abdominal X-ray NOS |
Erect plain X-ray of abdomen (procedure) |
ergometrinmaleat 200 µg/ml injektionsvæske, opløsning, ampul |
Ergometrine 200 microgram/mL solution for injection |
Ergot compound allergy |
Allergy to ergot alkaloid (finding) |
Eribulin mesylate 0.5mg/mL conventional release solution for injection |
Product containing only eribulin in parenteral dose form (medicinal product form) |
Eribulin mesylate 0.5mg/mL solution for intravenous infusion |
Product containing only eribulin in parenteral dose form (medicinal product form) |
Erroneous concept |
Erroneous component (foundation metadata concept) |
ertapenem 1 g pulver til infusionsvæske, opløsning, hætteglas |
Ertapenem (as ertapenem sodium) 1 g powder for solution for injection vial |
Erwinia ananas |
Pantoea ananatis (organism) |
Erwinia cacticida |
Pectobacterium cacticida (organism) |
Erwinia cancerogena |
Enterobacter cancerogenus |
Erwinia carnegieana |
Genus Dickeya (organism) |
Erwinia carotovora |
Pectobacterium carotovorum (organism) |
Erwinia carotovora ss. atroseptica |
Pectobacterium atrosepticum (organism) |
Erwinia carotovora ss. betavasculorum |
Pectobacterium betavasculorum (organism) |
Erwinia carotovora ss. carotovora |
Pectobacterium carotovorum subspecies carotovorum (organism) |
Erwinia carotovora subsp odorifera |
Pectobacterium carotovorum subspecies odoriferum (organism) |
Erwinia cartovora subsp cartobora |
Pectobacterium carotovorum subspecies carotovorum (organism) |
Erwinia cartovora subsp wasabiae |
Pectobacterium wasabiae (organism) |
Erwinia chrysanthemi |
Dickeya chrysanthemi (organism) |
Erwinia cypripedii |
Pantoea cypripedii (organism) |
Erwinia herbicola |
Pantoea agglomerans |
Erwinia nigrifluens |
Brenneria nigrifluens (organism) |
Erwinia paradisiaca |
Dickeya paradisiaca (organism) |
Erwinia quercina |
Lonsdalea quercina (organism) |
Erwinia rhapontici |
Pectobacterium rhapontici (organism) |
Erwinia rubrifaciens |
Brenneria rubrifaciens (organism) |
Erwinia salicis |
Brenneria salicis (organism) |